Search - tctmd.com

Displaying 241 - 260 of 367

Sort: Relevancy | Date

Presentation ARCH 2022

First Things First – Pharmacotherapy for HFrEF

Presenter: Georges Chahoud

April 23, 2022

News Daily News

Underuse of GDMT for Heart Failure Even Worse in Low-Income Countries

Todd Neale

April 20, 2022

News Daily News

Infertility in Women Linked to Subsequent Risk of HFpEF

L.A. McKeown

April 19, 2022

News Daily News

Revascularization’s Benefits in HFrEF Linked to Gains in LV Function

Caitlin E. Cox

April 15, 2022

News Conference News ACC 2022

DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF

L.A. McKeown

April 08, 2022

News Conference News ACC 2022

METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF

Todd Neale

April 08, 2022

Presentation ACC 2022

The Effect Of Omecamtiv Mecarbil On Exercise Tolerance In Patients With Chronic Heart Failure And Reduced Ejection Fraction: METEORIC-HF

Presenter: Michael Felker

April 04, 2022

News Conference News ACC 2022

PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization

L.A. McKeown

April 03, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Daily News

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

L.A. McKeown

March 22, 2022

News Daily News

Guideline-Directed Therapies Underused in Frail HF Patients

L.A. McKeown

March 11, 2022

News Opinion CV Team Dispatch

March 2022 News Roundup

L.A. McKeown

March 01, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Conference News THT 2022

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

L.A. McKeown

February 07, 2022

News Conference News THT 2022

Early Positive Signals From RELIEVE-HF Shift Discussion to Atrial Shunt Size

Shelley Wood

February 02, 2022

Presentation THT 2022

Clinical Data and Patient Experience with Barostim

Presenter: Nirav Raval

February 02, 2022

Presentation THT 2022

Mechanism of Action of Baroreflex Activation Therapy

Presenter: Marat Fudim

February 02, 2022

Presentation THT 2022

The Need for Device Therapy in HFrEF

Presenter: William Abraham

February 02, 2022

Presentation THT 2022

The Cunundrum of Afib and HFrEF / HFpEF

Presenter: Nassir Marrouche

February 02, 2022

Presentation THT 2022

Vagal Nerve Stimulation and ANTHEM-HFrEF

Presenter: Marvin A. Konstam

February 02, 2022

Advertisement

First Things First – Pharmacotherapy for HFrEF

Underuse of GDMT for Heart Failure Even Worse in Low-Income Countries

Infertility in Women Linked to Subsequent Risk of HFpEF

Revascularization’s Benefits in HFrEF Linked to Gains in LV Function

DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF

METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF

The Effect Of Omecamtiv Mecarbil On Exercise Tolerance In Patients With Chronic Heart Failure And Reduced Ejection Fraction: METEORIC-HF

PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

Guideline-Directed Therapies Underused in Frail HF Patients

March 2022 News Roundup

FDA Approves Empagliflozin for Treatment of HFpEF

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

Early Positive Signals From RELIEVE-HF Shift Discussion to Atrial Shunt Size

Clinical Data and Patient Experience with Barostim

Mechanism of Action of Baroreflex Activation Therapy

The Need for Device Therapy in HFrEF

The Cunundrum of Afib and HFrEF / HFpEF

Vagal Nerve Stimulation and ANTHEM-HFrEF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content